Squarepoint
DMAC icon

Squarepoint’s DiaMedica Therapeutics DMAC Stock Holding History

Squarepoint’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.02M Buy
+145,247
New +$893K ﹤0.01% 2877
2021
Q2 		– Sell
-35,536
Closed -$325K – 3336
2021
Q1 		$325K Buy
+35,536
New +$332K ﹤0.01% 2339

Other funds holding DMAC

CLG
Cooperman Leon G $3.55B AUM 41.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Squarepoint's DMAC Position: Q2 2026 in Review

Squarepoint opened a new position in DiaMedica Therapeutics (DMAC) in Q2 2026: 145,247 shares worth $1.02M. The stake represents ﹤0.01% of the portfolio and ranks #2877 among its holdings. This is a return to the name: Squarepoint previously reported a position in DMAC as recently as Q1 2021.

Squarepoint first reported a position in DMAC in Q1 2021 and has held it in 2 quarters since. 89 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

  • Squarepoint held 145,247 shares of DiaMedica Therapeutics worth $1.02M as of Q2 2026.
  • DiaMedica Therapeutics was a new Squarepoint position in Q2 2026.
  • DiaMedica Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #2877 holding.
  • Squarepoint first reported a position in DiaMedica Therapeutics in Q1 2021 and has held it in 2 quarters since.
  • 89 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.